NYSE:ADCT ADC Therapeutics (ADCT) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ADCT Stock Alerts $3.57 -0.11 (-2.99%) (As of 03:45 PM ET) Add Compare Share Share Today's Range$3.37▼$3.8850-Day Range$3.64▼$5.0952-Week Range$0.36▼$6.04Volume708,803 shsAverage Volume720,638 shsMarket Capitalization$295.52 millionP/E RatioN/ADividend YieldN/APrice Target$7.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ADC Therapeutics alerts: Email Address ADC Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside103.1% Upside$7.25 Price TargetShort InterestHealthy1.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$133,195 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.86) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 starsMedical Sector547th out of 931 stocksPharmaceutical Preparations Industry246th out of 433 stocks 3.3 Analyst's Opinion Consensus RatingADC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageADC Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about ADC Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.36% of the float of ADC Therapeutics has been sold short.Short Interest Ratio / Days to CoverADC Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADC Therapeutics has recently increased by 16.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldADC Therapeutics does not currently pay a dividend.Dividend GrowthADC Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADCT. Previous Next 2.1 News and Social Media Coverage News SentimentADC Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ADC Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for ADCT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $133,195.00 in company stock.Percentage Held by InsidersOnly 4.05% of the stock of ADC Therapeutics is held by insiders.Percentage Held by Institutions41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADC Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ADC Therapeutics are expected to grow in the coming year, from ($1.86) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADC Therapeutics is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADC Therapeutics is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ADC Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About ADC Therapeutics Stock (NYSE:ADCT)ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Read More ADCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADCT Stock News HeadlinesMay 10, 2024 | insidertrades.comAmeet Mallik Sells 29,731 Shares of ADC Therapeutics SA (NYSE:ADCT) StockMay 15, 2024 | globenewswire.comADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 10, 2024 | finance.yahoo.comADC Therapeutics First Quarter 2024 Earnings: In Line With ExpectationsMay 9, 2024 | finance.yahoo.comInsider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)May 9, 2024 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceMay 9, 2024 | globenewswire.comADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth OutlookMay 7, 2024 | finance.yahoo.comADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call TranscriptMay 6, 2024 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded WarrantsMay 6, 2024 | finance.yahoo.comADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded WarrantsMay 6, 2024 | investorplace.comADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024May 6, 2024 | globenewswire.comADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 6, 2024 | globenewswire.comADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone LymphomaMay 1, 2024 | globenewswire.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanMay 1, 2024 | finance.yahoo.comADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024April 30, 2024 | seekingalpha.comADCT ADC Therapeutics SAApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial ProgressApril 4, 2024 | msn.comADC Therapeutics gains after data for lymphoma therapyApril 4, 2024 | globenewswire.comADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaApril 3, 2024 | globenewswire.comADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024April 1, 2024 | finance.yahoo.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanMarch 16, 2024 | finance.yahoo.comUS$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These ResultsMarch 15, 2024 | seekingalpha.comADC Therapeutics SA (ADCT) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finance.yahoo.comQ4 2023 ADC Therapeutics SA Earnings CallMarch 13, 2024 | finance.yahoo.comADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic ResetSee More Headlines Receive ADCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today5/28/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:ADCT CUSIPN/A CIK1771910 Webwww.adctherapeutics.com Phone41-21-653-0200FaxN/AEmployees273Year FoundedN/APrice Target and Rating Average Stock Price Target$7.25 High Stock Price Target$11.00 Low Stock Price Target$2.00 Potential Upside/Downside+103.1%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-240,050,000.00 Net Margins-330.17% Pretax Margin-267.68% Return on Equity-1,313.37% Return on Assets-55.36% Debt Debt-to-Equity RatioN/A Current Ratio4.61 Quick Ratio4.35 Sales & Book Value Annual Sales$69.56 million Price / Sales4.25 Cash FlowN/A Price / Cash FlowN/A Book Value($1.93) per share Price / Book-1.85Miscellaneous Outstanding Shares82,780,000Free Float79,425,000Market Cap$295.52 million OptionableOptionable Beta1.69 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Ameet Mallik M.B.A. (Age 51)M.S., CEO & Director Comp: $1.84MMr. Jose I. Carmona M.B.A. (Age 52)Chief Financial Officer Comp: $884.86kDr. Mohamed Zaki M.D. (Age 59)Ph.D., Chief Medical Officer Comp: $2.41MMs. Lisa Michelle KalleboCorporate Controller & Chief Accounting OfficerDr. Michael Mulkerrin Ph.D. (Age 69)Chief Technical Operations Officer Dr. Patrick van Berkel Ph.D. (Age 56)Chief Scientific Officer Amanda HamiltonInvestor Relations OfficerMr. Peter J. Graham Esq. (Age 57)Chief Legal Officer Ms. Eugenia LitzVice President of Investor Relations & Corporate CommunicationsMs. Kimberly Pope (Age 57)Senior VP & Chief People Officer More ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRMersana TherapeuticsNASDAQ:MRSNC4 TherapeuticsNASDAQ:CCCCVerve TherapeuticsNASDAQ:VERVCytomX TherapeuticsNASDAQ:CTMXView All CompetitorsInsiders & InstitutionsSanibel Captiva Trust Company Inc.Bought 103,000 shares on 5/21/2024Ownership: 0.124%Redmile Group LLCSold 59,100 shares on 5/16/2024Ownership: 18.446%Ameet MallikSold 29,731 sharesTotal: $133,194.88 ($4.48/share)Hennion & Walsh Asset Management Inc.Bought 4,700 shares on 4/17/2024Ownership: 0.086%View All Insider TransactionsView All Institutional Transactions ADCT Stock Analysis - Frequently Asked Questions Should I buy or sell ADC Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ADCT shares. View ADCT analyst ratings or view top-rated stocks. What is ADC Therapeutics' stock price target for 2024? 5 Wall Street analysts have issued twelve-month price targets for ADC Therapeutics' shares. Their ADCT share price targets range from $2.00 to $11.00. On average, they expect the company's stock price to reach $7.25 in the next twelve months. This suggests a possible upside of 103.1% from the stock's current price. View analysts price targets for ADCT or view top-rated stocks among Wall Street analysts. How have ADCT shares performed in 2024? ADC Therapeutics' stock was trading at $1.66 at the start of the year. Since then, ADCT stock has increased by 115.1% and is now trading at $3.57. View the best growth stocks for 2024 here. Are investors shorting ADC Therapeutics? ADC Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,000,000 shares, an increase of 16.6% from the April 30th total of 857,600 shares. Based on an average daily trading volume, of 566,800 shares, the short-interest ratio is presently 1.8 days. Currently, 1.4% of the company's stock are sold short. View ADC Therapeutics' Short Interest. When is ADC Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our ADCT earnings forecast. How were ADC Therapeutics' earnings last quarter? ADC Therapeutics SA (NYSE:ADCT) announced its quarterly earnings data on Monday, May, 6th. The company reported ($0.56) EPS for the quarter, meeting analysts' consensus estimates of ($0.56). The business had revenue of $18.05 million for the quarter, compared to analyst estimates of $18.19 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 1,313.37% and a negative net margin of 330.17%. During the same period last year, the company posted ($0.74) EPS. What other stocks do shareholders of ADC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX). When did ADC Therapeutics IPO? ADC Therapeutics (ADCT) raised $126 million in an IPO on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO. Who are ADC Therapeutics' major shareholders? ADC Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Redmile Group LLC (18.45%), Sanibel Captiva Trust Company Inc. (0.12%), Hennion & Walsh Asset Management Inc. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of ADC Therapeutics? Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ADCT) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe 7th Trillion Dollar Company?The Oxford ClubThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesWARNING about the death of the U.S. dollar…Colonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
